Edwards Lifesciences (NYSE:EW) PT Lowered to $70.00 at Evercore ISI

Edwards Lifesciences (NYSE:EW) had its target price trimmed by Evercore ISI from $76.00 to $70.00 in a report published on Tuesday morning, Benzinga reports. They currently have an in-line rating on the medical research company’s stock.

EW has been the topic of a number of other research reports. Barclays reduced their price target on Edwards Lifesciences from $90.00 to $80.00 and set an overweight rating on the stock in a research report on Monday, September 9th. Canaccord Genuity Group cut their target price on Edwards Lifesciences from $85.00 to $77.00 and set a hold rating on the stock in a research report on Thursday, July 25th. Citigroup upped their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the company a buy rating in a research report on Wednesday, July 10th. TD Cowen lowered Edwards Lifesciences from a buy rating to a hold rating and cut their target price for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Finally, Daiwa America upgraded Edwards Lifesciences to a strong-buy rating in a research report on Wednesday, July 31st. Sixteen analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of Hold and a consensus target price of $78.23.

Edwards Lifesciences Trading Up 0.3 %

NYSE EW opened at $65.37 on Tuesday. The business’s 50-day moving average price is $66.58 and its two-hundred day moving average price is $81.28. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $39.39 billion, a PE ratio of 28.18, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the previous year, the company posted $0.66 EPS. The business’s revenue was up 6.7% on a year-over-year basis. On average, analysts expect that Edwards Lifesciences will post 2.71 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,218,138 over the last ninety days. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences in the second quarter worth $29,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences in the first quarter worth $34,000. Webster Bank N. A. purchased a new stake in Edwards Lifesciences in the second quarter worth $39,000. Finally, Versant Capital Management Inc increased its position in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after buying an additional 326 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.